United Therapeutics Corporation

NASDAQ:UTHR

301.42 (USD) • At close May 9, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998
Revenue 2,877.42,327.51,936.31,685.51,483.31,448.81,627.81,725.31,598.81,465.7611,288.5191,116.984916.076743.183603.831369.848281.497210.943159.632115.91573.5953.34130.125.7322.0490.40.1
Cost of Revenue 309.7257.5146.7122.5108.1117.6198.7105.772.769.036125.883131.127119.29788.90473.46545.32130.06622.26117.02812.3158.256.7835.4563.1371.7061.40
Gross Profit 2,567.72,0701,789.61,5631,375.21,331.21,429.11,619.61,526.11,396.7251,162.636985.857796.779654.279530.366324.527251.431188.682142.604103.665.3446.55824.6642.5950.343-10.1
Gross Profit Ratio 0.8920.8890.9240.9270.9270.9190.8780.9390.9550.9530.9020.8830.870.880.8780.8770.8930.8940.8930.8940.8880.8730.8190.4530.168-2.51
Reseach & Development Expenses 481408322.9540.1357.71,182.6357.9264.6147.6245.098242.549299.348173.387180.015166.761122.188239.18183.35257.5736.05230.60235.41726.77832.5970.18830.711
General & Administrative Expenses 542.3395.3416.2402.6369275.5206.7265.8232.2358.315299.2870000000000011.44216.94311.73650
Selling & Marketing Expenses 96.381.870.864.454.960.759.164.384.694.29782000000000004.4473,384.376000
SG&A 638.6477.1487467423.9336.2265.8330.1316.8452.612381.287394.01201.746156.482199.6176.33894.30699.02754.02824.65521.52922.66715.88916.94311.73652.4
Other Expenses 71.10-40.242.249.322.6-7.713.22.40.1573.9720.63531.866156.482199.6176.33894.30699.02756.05224.65521.52922.66715.8890-0.08-1.32.4
Operating Expenses 1,190.7885.1809.91,007.1781.61,518.8623.7594.7464.4697.71623.836693.358375.133336.497366.361298.526333.487182.379113.62260.70752.13158.08442.66749.53381.84434.413.4
Operating Income 1,3771,184.9979.7555.9593.6-187.6805.4814.91,061.7699.015538.8292.499421.646317.782164.00526.001-82.0566.30328.98242.89313.209-11.526-18.003-46.939-81.501-35.4-13.3
Operating Income Ratio 0.4790.5090.5060.330.4-0.1290.4950.4720.6640.4770.4180.2620.460.4280.2720.07-0.2910.030.1820.370.179-0.216-0.598-8.189-39.771-88.5-133
Total Other Income Expenses Net 16289.4-29.13845.322.6-46.5-45.4-1.5345.422-13.6-13.59619.025-18.665-16.166-7.2349.75810.2810.9264.6292.241.557-5.6489.651-4.6810.0640.546
Income Before Tax 1,5391,274.3950.6593.9638.9-165758.9769.51,060.21,044.437525.18278.903440.671299.117147.83918.767-72.29816.58339.90847.52215.449-9.969-23.651-37.288-86.182-35.3-12.8
Income Before Tax Ratio 0.5350.5470.4910.3520.431-0.1140.4660.4460.6630.7130.4080.250.4810.4020.2450.051-0.2570.0790.250.410.21-0.187-0.785-6.506-42.055-88.25-128
Income Tax Expense 343.9289.5223.3118.1124.1-60.5169.7351.6346.5392.798185.106104.343136.22981.87441.923-0.695-29.509-3.276-34.057-17.494-3.025-2.515.439-9.651-5.892-1.90
Net Income 1,195.1984.8727.3475.8514.8-104.5589.2417.9713.7651.639340.074174.56304.442217.868105.91619.462-42.78919.85973.96565.01615.449-9.969-23.651-37.288-75.608-33.5-12.8
Net Income Ratio 0.4150.4230.3760.2820.347-0.0720.3620.2420.4460.4450.2640.1560.3320.2930.1750.053-0.1520.0940.4630.5610.21-0.187-0.785-6.506-36.896-83.75-128
EPS 26.4421.0415.9810.611.65-2.3913.549.516.2914.177.063.495.843.811.890.37-0.930.471.611.430.36-0.24-0.57-0.92-1.97-1.26-0.77
EPS Diluted 24.6419.811510.0611.54-2.3913.399.3115.2512.726.283.285.713.671.780.35-0.930.441.531.290.33-0.24-0.57-0.92-1.97-1.26-0.77
EBITDA 1,654.41,386.81,040.3736.8646.3-74.9838.41,053.41,090.81,082.093575.017323.758484.455341.019185.47343.036-67.74622.18528.98250.08517.834-9.201-14.868-43.424-81.58-36.664-13.8
EBITDA Ratio 0.5750.5960.5370.4370.436-0.0520.5150.6110.6820.7380.4460.290.5290.4590.3070.116-0.2410.1050.1820.4320.242-0.172-0.494-7.576-39.81-91.659-138